Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HELPBullishIndustry Newsnews

High materiality8/10

Helus Pharma completes Phase 3 enrollment for HLP003; topline data due Q4 2026

Jul 21, 2026, 7:53 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Completion of Phase 3 enrollment reduces execution risk and sets a clear timeline for topline data, a near-term catalyst likely to attract capital interest. Positive Phase 2 durability and peer demand signals further support upside potential, though execution risk and ultimate NDA success remain.

AI summary

What happened, with direct paths to the underlying reporting

Helus Pharma reports completion of enrollment in the APPROACH Phase 3 trial for HLP003 in MDD, signaling progress toward topline data in Q4 2026. The program also includes EMBRACE and the EXTEND long-term study, with FDA Breakthrough Therapy Designation supporting potential regulatory progress. Positive Phase 2 durability data and SPRAVATO's sales growth underscore rising interest in innovative depression treatments.

Helus Pharma completes APPROACH Phase 3 enrollment for HLP003 in MDD.
Topline data expected in Q4 2026; potential FDA NDA in 2028.
Phase 2 data showed durable efficacy with ~23-point MADRS reduction.
EMBRACE enrollment ongoing; EXTEND rollover may extend safety/durability data.
SPRAVATO growth cited as backdrop; Helus aims NSAs as durable depression solutions.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Helus Pharma completes Phase 3 enrollment for HLP003; topline data due Q4 2026

Helus Pharma Shares Fall Despite Ph II Results Announcement for HLP004